+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years - 65Years
All Genders
ID07016321

Evaluating Oral Emetine for Treatment of Dengue Fever in Symptomatic Adults A Randomized, Double-Blind, Placebo-Controlled Trial

Led by Johns Hopkins University · Updated on 2026-10-13

600

Participants Needed

2

Research Sites

9 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effects of oral emetine in patients aged 18 to 65 years who have symptomatic dengue fever. This study aims to determine whether emetine can reduce 28-day mortality or progression to severe dengue, including severe plasma leakage, bleeding, or organ involvement. It also assesses the safety of emetine, including serious side effects and toxicities. Dengue fever is a significant global health concern transmitted by mosquitoes, with no proven antiviral treatment currently available, and this study explores emetines potential as an antiviral agent. Participants will receive one of three treatments 6 mg emetine, 12 mg emetine, or a placebo pill taken orally for 10 consecutive days. The study is randomized, double-blinded, and placebo-controlled, ensuring unbiased assessment across groups. Blood samples will be collected for at least five days to monitor viral load, inflammatory markers, and safety parameters. The research builds on previous studies indicating emetines antiviral activity at low doses without significant cardiovascular toxicity. During the study, participants will be monitored daily by healthcare staff who will record vital signs and symptoms for clinical assessments over 28 days. Blood tests will measure changes in viral load and various inflammatory markers, while questionnaires will assess fatigue after infection on day 28. The primary outcomes focus on mortality, disease progression, and safety events within 28 days. Participants will be closely followed to track recovery time, viral clearance, and any adverse reactions throughout the trial.

CONDITIONS

Brief Title

Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)

Research Team

K

Kunchok Dorjee, MBBS, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here